Abstract
(Z)-5-(4-Methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene (2) is the key intermediate for the preparation of several anticancer agents, belonging to the group of aminocombretastatins (AC7739, AVE8062). Synthesis of the title compounds was achieved by a modified Wittig reaction under Boden’s conditions using potassium carbonate as a base and 18-crown-6 as a phase transfer catalyst. Both π-diastereoisomers were characterized by single crystal X-ray diffraction analysis, 1H and 13C NMR spectroscopy. (E)-5-(4-Methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene (1) crystallizes in the orthorhombic space group Pbca (N° 61) with one molecule per asymmetric unit while (Z)-5-(4-methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene (2) crystallizes in the monoclinic space group P21/c (N° 14) also with one molecule per asymmetric unit. In both compounds no typical hydrogen bonding interactions could be located. The three-dimensional crystal structure is stabilized by C–H···O interactions. The cytotoxicity of synthesized nitrocombretastatins was also evaluated. The Z-stilbene 2 inhibited cell growth with IC50 of 0.15 and 0.11 µM following 72 h treatment in EA.hy926 and MG-63 cell lines.
Graphical Abstract
Synthesis, crystal structure and cytotoxic properties of two stilbene derivatives (E)- and (Z)-5-(4-methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene are reported. The compounds can be examined as precursors for the synthesis of combretastatin A-4 analogues.
Similar content being viewed by others
References
Wolter F, Stein J (2002) Drugs Future 27:949
Piotrowska H, Kucinska M, Murias M (2012) Mut Res 750:60
Estrela JM, Ortega A, Mena S, Rodriguez ML, Asensi M (2013) Crit Rev Clin Lab Sci 50:65
Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA (2006) J Med Chem 49:3033
Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, Hogan F (1995) J Med Chem 38:1666
McGown AT, Fox BW (1990) Cancer Chemother Pharmacol 26:79
Nam H-X (2003) Curr Med Chem 10:1697
Cirla A, Mann J (2003) Nat Prod Rep 20:558
Hsieh HP, Liou JP, Mahindroo N (2005) Curr Pharmaceut Design 11:1655
Chaudhary A, Pandeya SN, Kumar P, Sharma PP, Gupta S, Soni N, Verma KK, Bhardwaj G (2007) Mini-Rev Med Chem 7:1186
Singh R, Kaur H (2009) Synthesis 2009:2471
Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T (1998) J Med Chem 41:3022
Ohsumi K, Hatanaka T, Nakagawa R, Fukuda Y, Morinaga Y, Suga Y, Nihei Y, Ohishi K, Akiyama Y, Tsuji T (1999) Anticancer Drug Des 14:539
Delmonte A, Sessa C (2009) Expert Opin Investig Drugs 18:1541
Mita MM, Sargsyan L, Mita AC, Spar M (2013) Expert Opin Investig Drugs 22:317
Pinney KG, Mejia MP, Villalobos VM, Rosenquist BE, Pettit GR, Verdier-Pinard P, Hamel E (2000) Bioorg Med Chem 8:2417
Kamal A, Shaik B, Nayak VL, Nagaraju B, Kapure JS, Malik MS, Shaik TB, Prasad B (2014) Bioorg Med Chem 22:5155
Coccetti P, Montano G, Lombardo A, Tripodi F, Orsini F, Pagliarin R (2010) Bioorg Med Chem Lett 20:2780
Boden R (1975) Synthesis 1975:784
Lara-Ochoa F, Espinosa-Pérez G (2007) Tetrahedron Lett 48:7007
Mosmann T (1983) J Immunol Methods 65:55
Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM (1987) J Nat Prod 50:119
CrysAlis PRO (2011) Agilent Technologies. UK Ltd, Yarnton, England
Sheldrick GM (2008) Acta Cryst A 64:112
Farrugia L (2012) J Appl Crystallogr 45:849
Macrae CF, Bruno IJ, Chisholm JA, Edgington PR, McCabe P, Pidcock E, Rodriguez-Monge L, Taylor R, van de Streek J, Wood PA (2008) J Appl Cryst 41:466
Acknowledgments
This work was supported by the Sofia University Scientific Research Fund (Grant 24/2014) and by the Ministry of Education and Science of Bulgaria (Grant DRNF02/1).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Gerova, M.S., Encheva, G.R., Nikolova, R.P. et al. Synthesis, Crystal Structure and Cytotoxic Properties of Nitrocombretastatins (E)- and (Z)-5-(4-Methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene. J Chem Crystallogr 46, 105–112 (2016). https://doi.org/10.1007/s10870-016-0633-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10870-016-0633-3